Loading
CO
Citius Oncology, Inc. Stock: price and insider trades · United States
US·Mcap US$68.6M
Citius Oncology, Inc.: what insiders have been doing
Every trade that managers of Citius Oncology, Inc. disclose to SEC (Form 4) is tracked on this page. Between 24 October 2025 and 24 October 2026, 10 insiders published 20 filings.
Not one of the filings records a straightforward purchase or sale on the market. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
For context, the typical company on the same exchange (median of 5,808 companies) published 19 filings over the same period, against 20 filings here. In its latest annual report filed with the SEC (10-K, fiscal year ended 30 September 2025), the company reported net income of -24.8 m USD.
No insider has bought Citius Oncology, Inc. shares on the open market in the past twelve months.
In the same market, recent insider purchases at GameStop Corp. and Heico Corp also feature in our signals. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
32
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
n/a
n/a
Analyst consensus: bullish or bearish?
Analysts rate Citius Oncology, Inc. Buy (bullish), based on 1 analysts. Average price target: US$4.00.
Financial data
as of FY 2025FY ended September 2025 · cache
US$0.74
Analyst consensus
1 analystsBuy
US$4.00Target US$4.00(+442%)US$4.00
Income statement
EBITDA-US$23.5M
Net income-US$24.8M0.0% margin
Valuation
P/Book1.9x
Beta3.49
Balance sheet & cash
Market capUS$68.6M
Total debtUS$3.8M
Free Cash Flow-US$11.2M
Debt / Equity11%
Profitability & ownership
ROE-119.9%
ROA-28.3%
% insiders77.5%
% institutions15.3%
Last declaration on 22 December 2025
Declarations32 total
850,000 shares0Common StockSEC:0001213900-25-124536:0
1,700,000 shares0Common StockSEC:0001213900-25-124533:0
300,000 shares0Common StockSEC:0001213900-25-124532:0
300,000 shares0Common StockSEC:0001213900-25-124530:0
300,000 shares0Common StockSEC:0001213900-25-124529:0
300,000 shares0Common StockSEC:0001213900-25-124528:0
300,000 shares0Common StockSEC:0001213900-25-124537:0
825,000 shares0Common StockSEC:0001213900-25-124535:0
825,000 shares0Common StockSEC:0001213900-25-124534:0
300,000 shares0Common StockSEC:0001213900-25-124531:0
300,000 shares0Common StockSEC:0001213900-25-116682:0
300,000 shares0Common StockSEC:0001213900-25-116681:0
300,000 shares0Common StockSEC:0001213900-25-116680:0
300,000 shares0Common StockSEC:0001213900-25-116679:0
850,000 shares0Common StockSEC:0001213900-25-116678:0
825,000 shares0Common StockSEC:0001213900-25-116677:0
300,000 shares0Common StockSEC:0001213900-25-116676:0
1,700,000 shares0Common StockSEC:0001213900-25-116675:0
825,000 shares0Common StockSEC:0001213900-25-116673:0
300,000 shares0Common StockSEC:0001213900-25-116674:0
825,000 shares0Common StockSEC:0001213900-25-090609:0
300,000 shares0Common StockSEC:0001213900-25-090608:0
300,000 shares0Common StockSEC:0001213900-25-090610:0
825,000 shares0Common StockSEC:0001213900-25-090611:0
300,000 shares0Common StockSEC:0001213900-25-090612:0
25 of 32 declarations
About Citius Oncology, Inc.
Citius Oncology, Inc. is a company focused on developing innovative cancer treatments. It aims to improve outcomes for patients with oncological diseases.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations
